Fostamatinib

Drug Profile

Fostamatinib

Alternative Names: FosD; Fostamatinib disodium; Fostamatinib sodium; R 985788; R-406/788; R-788; R-935/788; R788 sodium; R935788 sodium; Tamatinib fosdium; Tavalisse

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Rigel Pharmaceuticals
  • Developer AstraZeneca; Duke University Medical Center; Rigel Pharmaceuticals
  • Class Anti-inflammatories; Antianaemics; Antirheumatics; Oxazines; Phosphoric acid esters; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action B cell inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immune thrombocytopenic purpura
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Immune thrombocytopenic purpura
  • Phase II Autoimmune haemolytic anaemia; IgA nephropathy
  • Phase I Graft-versus-host disease
  • Discontinued Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Rheumatoid arthritis; Solid tumours; Systemic lupus erythematosus; T cell lymphoma; Type 1 diabetes mellitus

Most Recent Events

  • 27 Apr 2017 Rigel Pharmaceuticals applies for federal registration of Tavalisse™ mark with US Patent and Trademark Office for fostamatinib in USA
  • 17 Apr 2017 Preregistration for Immune thrombocytopenic purpura in USA (PO)
  • 17 Apr 2017 Rigel Pharmaceuticals expects to receives notification regarding the NDA acceptance from the FDA for fostamatinib in Immune thrombocytopenic purpura, by June 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top